Palatin Technologies Inc. (PTN)

[chemist72]

NEWS today: Good, not so good and bad.

First, the good.

"Both Phase 3 studies met their co-primary endpoints of improvements in desire (as measured by the Female Sexual Function Index – Desire domain (FSFI-D)) and decrease in associated distress (as measured by the Female Sexual Distress Scale – Desire/Arousal/Orgasm (FSDS-DAO))." This was reported back in November.

More good stuff.

"Rekynda was associated with statistically significant improvements in the total FSFI score including arousal, lubrication, orgasm, and satisfaction domain scores (all p≤0.01). Scores for satisfaction with desire and arousal on the Female Sexual Encounter Profile-Revised showed statistically significant improvement from baseline in Study 301 (p≤0.01) ..."

Not so good.

"... but did not reach statistical significance in Study 302."

Finally, the bad.

"Changes in the number of satisfying sexual events (SSEs) showed some improvement but were not significantly different in either study." This is basically what Feuerstein said back in November. So I have to give him some credit also.